Features Partner Sites Information LinkXpress
Sign In
Demo Company

Bacterial Quorum Sensing Molecule Targets Host Cell Migration Receptor

By BiotechDaily International staff writers
Posted on 19 Nov 2012
Print article
Scientists have discovered a new role and important target on human host cells for a signaling molecule known for its role in quorum sensing of the pathogenic bacteria Pseudomonas aeruginosa.

P. aeruginosa uses N-acylhomoserine lactones (AHLs) as signaling molecules in quorum sensing, whereby it coordinates expression and production of biofilm and virulence factors. AHLs can diffuse through bacterial and eukaryotic cell membranes. At low concentrations, white blood cells, for example, can become more flexible and effective, but at high concentrations the opposite occurs, which weakens immune defenses and increases likelihood of progressive infections and inflammations.

A research team at Linköping University (Linköping, Sweden) has now identified a signaling role for an AHL also in host cells by examining effects on human intestinal epithelial Caco-2 cells. The quorum sensing AHL molecule N-3-oxo-dodecanoyl-L-homoserine lactone (3O-C(12)-HSL) produced by P. aeruginosa was found to modulate Caco-2 cell migration in a dose- and time-dependent manner. The team then demonstrated for the first time that 3O-C(12)-HSL interacts and co-localizes with the IQ-motif-containing GTPase-activating protein (IQGAP1) in Caco-2 cells. Moreover, 3O-C(12)-HSL induced changes in the phosphorylation status of Rac1 and Cdc42 and in the localization of IQGAP1. The study, published online October 11, 2012 in the journal PLoS Pathogens, suggests that the IQGAP1 is a novel receptor for P. aeruginosa 3O-C(12)-HSL and is likely the integrator of Rac1 and Cdc42- dependent altered cell migration.

Prof. Elena Vikström, medical microbiologist and senior author of the study, describes IQGAP1 as something of a double agent — “The protein can both listen in on the bacteria’s communication and change the functions in its host cells,” said Prof. Vikström. She adds, “We have proof that physical contact between bacteria and epithelial cells is not always required; the influence can happen at a distance.” The team’s discovery can open the door to new strategies for treatment where antibiotics cannot help. One possibility is designing molecules that bind to the receptor and thereby block the signaling path for the bacteria; a strategy that could work with cystic fibrosis, for example, as the disease involves sticky mucus made of bacterial biofilm and large amounts of white blood cells formed in the airways.

Related Links:
Linköping University

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.